Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

BACKGROUND: The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sklarz, L.-M., Gladbach, Y. S., Ernst, M., Hamed, M., Roolf, C., Sender, S., Beck, J., Schütz, E., Fischer, S., Struckmann, S., Junghanss, C., Fuellen, G., Murua Escobar, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425054/
https://www.ncbi.nlm.nih.gov/pubmed/32817744
http://dx.doi.org/10.1186/s12935-020-01431-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425054/
https://www.ncbi.nlm.nih.gov/pubmed/32817744
http://dx.doi.org/10.1186/s12935-020-01431-4

Ejemplares similares